Azzeri A.Shabaruddin FH.Tan SS.McDonald SA.Dahlui M.Kamarulzaman A.Mohamed R.2024-05-282024-05-282018--0125-15622446-3https://doi.org/10.1016/j.jval.2017.08.1414https://www.valueinhealthjournal.com/article/S1098-3015(17)31748-5/fulltext?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301517317485%3Fshowall%3Dtrue#relatedArticleshttps://www.sciencedirect.com/science/article/pii/S1098301517317485https://oarep.usim.edu.my/handle/123456789/4554Value in Health Volume 20, Issue 9, October–November 2017, Page A632Objectives Chronic hepatitis C virus (HCV) infection is often asymptomatic until the occurrence of severe liver disease such as liver cirrhosis and liver cancer. These HCV-related clinical sequalae can cause significant clinical and financial implication. This study aims to describe the clinical characteristics of HCV-infected patients during initial presentation to tertiary care in Malaysia, a middle-income Asian country, to inform the development of a national guideline. Methods A descriptive cross-sectional study of a hospital-based case-series on consecutive HCV patients who presented in 2014 at the national referral centre was conducted. All patients with active viremia (detectable HCV RNA) during initial presentation were included. Results There were 741 HCV patients treated by the hepatology specialty in 2014 (n=741/5865). Mean age at initial presentation was 48 years (SD=11.5; median=49) with 541 (73%) being male. Prior known exposure to various HCV risk factors included: intravenous drug use (n=271/737), blood or blood products transfusion (n=237/737), multiple sexual partners (n=123/737), high-risk practices such as tattooing, cupping therapy, acupuncture and sharing of personal items with infected individuals (n=68/737), dialysis (n=38/737) and organ transplantation (n=13/737). Based on histology, fibroscan findings or aspartate aminotransferase-to-platelet ratio index (APRI), 327 (44.1%) patients had cirrhosis at initial presentation, with mean age 52 years (SD=8.86) compared to 44 years (SD=12.0) for non-cirrhotic patients. Decompensated cirrhosis was seen in 118 (36%) and HCC in 45 (13%) of the 327 cirrhotic patients. Only 262 (44%) of 595 patients who were clinically eligible for interferon-based therapy (patients with no cirrhosis or with compensated cirrhosis) received interferon-based HCV treatment. Conclusions HCV-infected patients at initial presentation to tertiary care in Malaysia reflected delayed presentation to clinical care with disproportionately high number of cirrhotic patients. The low proportion of clinically eligible patients receiving HCV treatment need to be investigated further and addressed accordingly in future guidelines.enArticle789798495